Diseases of the Endocrine System | Genetics - Adult | Genetics - Pediatric, Phase III

VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

Trial with
Vertex Pharmaceuticals, Inc.
Ages
12 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Marie Egan

marie.egan@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Marie Egan, MD
Professor of Pediatrics (Respiratory) and of Cellular And Molecular Physiology; Director, Cystic Fibrosis Center; Vice Chair for Research, Department of Pediatrics

Sub-Investigators

Last Updated
02/02/2024
Study HIC
#2000030926